Journal Watch · Journal of Controlled Release · 2026

Zn(II)-adjuvanted imidazole-based lipid nanoparticles for potent spleen-targeted mRNA delivery and enhanced immune activation.

Overall, this study underscores the potential of Zn(II)-coordinated LNPs as effective nanoplatforms for extrahepatic mRNA vaccine delivery, offering a promising strategy for the mRNA-based vaccine design and immunotherapies.

Han Y, Ma G, Zhang K et al.Journal of Controlled Release3 min readPharma relevance 70/100

DOI: 10.1016/j.jconrel.2026.114742PMID: 41720271Study type: research study

TL;DR

Overall, this study underscores the potential of Zn(II)-coordinated LNPs as effective nanoplatforms for extrahepatic mRNA vaccine delivery, offering a promising strategy for the mRNA-based vaccine design and immunotherapies.

Key findings

  • In a melanoma model, vaccination with Zn-A10-1 LNPs markedly suppressed tumor progression and promoted the infiltration of OVA-specific CD8<sup>+</sup> T cells.
  • Overall, this study underscores the potential of Zn(II)-coordinated LNPs as effective nanoplatforms for extrahepatic mRNA vaccine delivery, offering a promising strategy for the mRNA-based vaccine design and immunotherapies.

What they did

Initially, a library of 28 imidazole-based ionizable lipids was synthesized and screened, identifying A10-1 LNPs with a well-balanced lipid composition and high transfection efficiency. Furthermore, Zn<sup>2+</sup> coordination with the imidazole headgroup imparts Zn-A10-1 LNPs with enhanced structural stability and delivery performance, leading to improved cellular uptake, efficient endosomal escape, and preferential accumulation in the spleen. These attributes contributed to the robust activation of bone marrow-derived dendritic cells (BMDCs), induced memory T cell responses, and elevated proinflammatory cytokine secretion.

Full abstract (original)

Background: Lipid nanoparticles (LNPs) have emerged as a powerful nanoplatforms contributing to the success of mRNA vaccines. However, the rational design of lipid structures and the optimization of LNP composition, especially via metal-based adjuvants to boost extrahepatic delivery and immune responses, represent a promising yet technically challenging strategy. Herein, we developed a Zn(II)-adjuvanted imidazole-based LNP system that integrates rational lipid design with metal-coordinated self-assembly to achieve synergistic enhancement in delivery and immunogenicity.

What they did: Initially, a library of 28 imidazole-based ionizable lipids was synthesized and screened, identifying A10-1 LNPs with a well-balanced lipid composition and high transfection efficiency. Furthermore, Zn<sup>2+</sup> coordination with the imidazole headgroup imparts Zn-A10-1 LNPs with enhanced structural stability and delivery performance, leading to improved cellular uptake, efficient endosomal escape, and preferential accumulation in the spleen. These attributes contributed to the robust activation of bone marrow-derived dendritic cells (BMDCs), induced memory T cell responses, and elevated proinflammatory cytokine secretion.

Results & conclusions: In a melanoma model, vaccination with Zn-A10-1 LNPs markedly suppressed tumor progression and promoted the infiltration of OVA-specific CD8<sup>+</sup> T cells. Overall, this study underscores the potential of Zn(II)-coordinated LNPs as effective nanoplatforms for extrahepatic mRNA vaccine delivery, offering a promising strategy for the mRNA-based vaccine design and immunotherapies.

Abstract © the authors / Journal of Controlled Release (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.jconrel.2026.114742 · PubMed 41720271.

Why it matters for pharma & biotech

  • Directly relevant to teams in mRNA / delivery technology, vaccines — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: mRNA / delivery technology · vaccines

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Journal of Controlled Release study find?

Overall, this study underscores the potential of Zn(II)-coordinated LNPs as effective nanoplatforms for extrahepatic mRNA vaccine delivery, offering a promising strategy for the mRNA-based vaccine design and immunotherapies.

What type of study is this?

It is a research study, published in Journal of Controlled Release in 2026. Initially, a library of 28 imidazole-based ionizable lipids was synthesized and screened, identifying A10-1 LNPs with a well-balanced lipid composition and high transfection efficiency.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/j.jconrel.2026.114742. PubMed ID: 41720271. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Han Y, Ma G, Zhang K et al.. Zn(II)-adjuvanted imidazole-based lipid nanoparticles for potent spleen-targeted mRNA delivery and enhanced immune activation.. Journal of Controlled Release (2026). DOI: 10.1016/j.jconrel.2026.114742.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/zn-ii-adjuvanted-imidazole-based-lipid-nanoparticles-for-potent-spleen-t-114742/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides